Moderna posts Q1 2024 revenues at US$167 million
GAAP net loss of $1.2 billion and GAAP diluted EPS of $(3.07)
GAAP net loss of $1.2 billion and GAAP diluted EPS of $(3.07)
New advanced technology-enabled offering aims to streamline synthetic route identification for novel active pharmaceutical ingredients (APIs)
Parexel will leverage Palantir’s Foundry and Artificial Intelligence Platform to further power its clinical data platform
Around 7% of the Indian population suffers from IBS
CHL is strengthening its play in the fast-growing beauty and personal care sector
The exclusive agreement between AAHI and Croda includes a collaborative effort in research and development
Combination will create a Canadian Health Champion spanning generic, biosimilar and branded pharmaceuticals
Lunaphore's flagship COMET technology is the only fully-automated, high-throughput, hyperplex platform with superior tissue profiling capabilities
The facility will manufacture tablets, capsules, and injections for the oncology segment
Subscribe To Our Newsletter & Stay Updated